Key facts
- It has raised $2.5M; the latest was Early Stage VC ($2.5M) in Sep 2025.
- Notable investors include Gaingels, Harvard Innovation Launch Lab, Exitfund, 2048 Ventures, ZAKA VC — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for KiraGen Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for KiraGen Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KiraGen Bio
Developer of a biotechnology platform intended to unlock the full potential of CAR-T cells against solid tumors. The company's platform specializes in the development of artificial intelligence-driven design and multiplex gene editing to create CAR-T cells that can address the immunosuppressive barriers of the tumor microenvironment, enabling medical professionals to develop effective and durable treatments for solid tumors.
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2023
- Employees
- 5
- Website
- kiragenbio.com/
- Ownership
- Privately Held (backing)
KiraGen Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KiraGen Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KiraGen Bio in its N-PORT filings yet. We sweep new filings monthly.